Silvia Gramolelli | Health Safety and Environment | Best Researcher Award

Published on by Petroleum Engineering

Dr. Silvia Gramolelli | Health Safety and Environment | Best Researcher Award

Academy Research Fellow at Åbo Akademi University, Finland

Dr. Silvia Gramolelli is an accomplished cancer virologist whose work has significantly advanced our understanding of virus-host interactions in tumorigenesis. With a solid foundation in molecular biology and virology, she has dedicated her career to uncovering the molecular mechanisms by which cancer-associated viruses hijack human cells. Her expertise spans from molecular virology to translational cancer research, with a notable emphasis on the role of the Epstein-Barr Virus (EBV) in gastric cancer. Based in Finland, Dr. Gramolelli is a respected member of the academic community and a sought-after collaborator in international consortia. Her work is deeply embedded in cutting-edge research projects funded by the European Union and Finnish research councils. Her integrative approach combines experimental innovation with systems-level analyses, making her research both scientifically rigorous and translationally relevant. Dr. Gramolelli’s dedication to impactful science and knowledge dissemination continues to shape the future of viral oncology.

Profile

Orcid

Education

Dr. Gramolelli’s academic path is rooted in prestigious institutions across Europe. She completed her undergraduate and master’s studies in Italy, specializing in molecular biology and virology, which laid the groundwork for her future research trajectory. Her doctoral training took place at the University of Helsinki, Finland, under the supervision of leading virologists. During her PhD studies, she gained deep expertise in cellular signaling and the molecular basis of viral latency and reactivation. Her education emphasized strong methodological training in cell and molecular biology, proteomics, and gene expression analysis, which she would later apply in cancer virology contexts. The robust academic foundation she received enabled her to make early contributions to high-impact research publications and secure competitive postdoctoral opportunities. Her educational journey reflects a balance between foundational scientific learning and applied biomedical research, which has fueled her long-standing commitment to addressing urgent medical challenges through science.

Experience

Over the past decade, Dr. Gramolelli has accumulated a breadth of experience in both academic and translational research settings. She currently serves as a Senior Researcher at Åbo Akademi University in Finland, where she leads projects focused on EBV-associated gastric cancer. Prior to this, she held research positions at the University of Helsinki and contributed significantly to EU Horizon-funded projects such as DETECT EBV. In these roles, she has managed multidisciplinary teams and fostered collaborations across clinical and academic sectors. Her research spans cellular models, animal studies, and translational data analysis, demonstrating her adaptability and broad scientific competence. Beyond laboratory work, she has contributed to public science communication and policy discussions on cancer diagnostics. Her experience also includes mentorship of doctoral students and teaching graduate-level courses, reflecting her dedication to training the next generation of biomedical scientists. Dr. Gramolelli’s career path showcases consistent growth and increasing leadership in viral oncology.

Research Interests

Dr. Gramolelli’s research focuses on the intersection of virology, oncology, and immunology. Her primary interest lies in Epstein-Barr Virus (EBV) and its role in gastric cancer development, latency, and reactivation. She investigates how host factors, such as transcription factors and chromatin modifiers, interact with latent viruses and contribute to viral persistence or oncogenic reprogramming. Her studies also explore the mechanisms by which stress responses, such as heat shock or inflammation, can wake dormant viruses in cancer cells. This research aims to identify new therapeutic targets for virus-associated malignancies. Her lab integrates advanced proteomic analyses, CRISPR screening, and single-cell technologies to dissect complex virus-host interactions. Recent projects include studying the role of HSF2 in EBV reactivation and identifying biomarkers for early virus-related tumorigenesis. Her multidisciplinary and translational approach aims to bridge basic discoveries with clinical applications in cancer diagnostics and therapy.

Awards

Dr. Gramolelli’s excellence in cancer research has been recognized with the Per Brahe Prize 2023, awarded by Åbo Akademi University for her impactful work in the field of virus-associated gastric cancer. This prestigious award acknowledges both the scientific novelty and the translational potential of her findings. Her research has also been featured in numerous national and international media outlets, highlighting its relevance to public health and cancer diagnostics. She has been an invited speaker at various international symposia and serves as a reviewer for high-impact scientific journals. Her contributions have elevated the visibility of Finnish biomedical research on a global stage and provided new insights into virus-driven carcinogenesis. The recognition she has received speaks to her leadership in science, mentorship, and innovation, and positions her as a leading figure in the next generation of cancer researchers.

Publications

  1. Gramolelli, S., et al. (2024). HSF2-Driven Epstein-Barr Virus Reactivation and Cancer Linkage. PLOS Pathogens. Cited by 12 articles.

  2. Gramolelli, S., et al. (2023). Stress-Induced Viral Reactivation in Gastric Epithelium. Nature Communications. Cited by 15 articles.

  3. Gramolelli, S., et al. (2022). Host Chromatin Remodelers in EBV Latency. Journal of Virology. Cited by 9 articles.

  4. Gramolelli, S., et al. (2021). Therapeutic Targeting of EBV in Gastric Cancer. Cancers. Cited by 14 articles.

  5. Gramolelli, S., et al. (2020). Proteomics of Viral-Host Interaction Networks. Molecular & Cellular Proteomics. Cited by 11 articles.

  6. Gramolelli, S., et al. (2019). Virus Reactivation Pathways in Tumor Models. Oncogene. Cited by 10 articles.

  7. Gramolelli, S., et al. (2018). EBV and Cellular Senescence Crosstalk. Frontiers in Oncology. Cited by 13 articles.

Conclusion

Dr. Silvia Gramolelli exemplifies scientific excellence, innovation, and commitment to societal impact through her research in virus-associated cancers. Her work not only contributes critical knowledge to the understanding of EBV biology but also identifies new avenues for diagnostics and therapy in oncology. Through consistent academic achievements, impactful publications, and recognized awards, she has proven to be a leader in her field. Her contributions resonate beyond the lab, influencing cancer policy, early detection strategies, and public awareness. As an award nominee, she represents the intersection of scientific curiosity and translational application.

Pier Giorgio Natali | Health, Safety, and Environment (HSE) | Excellence in Research Award

Published on by Petroleum Engineering

Prof. Dr. Pier Giorgio Natali | Health, Safety, and Environment (HSE) | Excellence in Research Award

Investigator at G. D’Annunzio University, Chieti, Italy

Pier Giorgio Natali, MD, PhD (hc), is a distinguished scientist in the field of oncology with extensive contributions to cancer research, prevention, and advocacy. He has played a pivotal role in experimental immunopathology and translational oncology. With a career spanning several decades, he has held prestigious positions, including serving as President of the Italian Cancer Society and as the Scientific Director of the “Regina Elena” National Cancer Institute in Rome. His efforts have significantly influenced cancer education, policy-making, and early diagnosis strategies. He is also recognized as a key contributor to international cancer prevention initiatives, including his role as Co-Founder of the UNESCO Chart of Paris. With over 350 published studies and a high citation index, his research continues to shape modern oncology. Currently, he serves as the Secretary General of the Mediterranean Taskforce for Cancer Control (MTCC) and sits on the Advisory Board of CancerToday Magazine, advocating for cancer awareness and long-term survivorship issues.

Profile

Scopus

Education

Dr. Natali completed his medical degree at “La Sapienza” University of Rome, where he laid the foundation for his groundbreaking work in medicine. His academic journey took him to the United States, where he received specialized training in experimental immunopathology. His education and training provided him with the necessary expertise to delve into translational oncology, allowing him to bridge the gap between basic scientific research and clinical applications. Over the years, he has continuously expanded his knowledge through various research collaborations, international advisory roles, and participation in specialized oncology programs.

Professional Experience

Dr. Natali has an illustrious career in cancer research and oncology. He has served as the President of the Italian Cancer Society and as the Scientific Director of the “Regina Elena” National Cancer Institute. He has been a part of multiple strategic international advisory committees and scientific journal editorial boards, influencing policy and research direction. His contributions extend beyond academia, with his involvement in industry projects as an investigator at Janus Pharma Srl in Rome. His advisory roles with leading cancer organizations and contributions to the UNESCO Chart of Paris highlight his dedication to global cancer control initiatives. Additionally, he holds an emeritus position at the Collegium Ramazzini, further solidifying his impact in public health and cancer research.

Research Interests

Dr. Natali’s primary research interests lie in translational oncology, cancer immunology, and molecular oncology. He has dedicated his career to improving cancer diagnosis, treatment, and prevention. His work has focused on the characterization of tumor-associated antigens, the development of monoclonal antibodies for cancer therapy, and the molecular mechanisms underlying tumor progression. He has also contributed significantly to research on non-communicable diseases, particularly through his involvement in the development of functional foods aimed at improving health outcomes. His research collaborations have extended internationally, making notable advancements in the fight against cancer through both laboratory and clinical applications.

Awards and Honors

Dr. Natali has been recognized for his exceptional contributions to oncology with numerous awards and honors. His achievements in cancer research, prevention, and advocacy have earned him national and international acclaim. He has received prestigious accolades for his pioneering work in experimental immunopathology and translational oncology. His role in shaping cancer research policies and his efforts in public health awareness have further cemented his reputation as a leader in the field. His contributions to medical literature and the scientific community have also been acknowledged through invitations to serve on advisory boards and scientific committees.

Selected Publications

  1. Natali P.G., Pellegrino M.A., Wilson B.S., Ng A.K., Imai K., Indiveri F., Ferrone S. (1981). “Ia-like antigens on human melanoma cells.” Hybridomas in Cancer Diagnosis and Treatment, Raven Press. Cited by 120 articles.
  2. Natali P.G., Russo C., Ng A.K., Giacomini P., Indiveri F., Pellegrino M.A., Ferrone S. (1982). “Tissue distribution of human Ia-like antigens.” Immunobiology of the Major Histocompatibility Complex, Karger Press. Cited by 150 articles.
  3. Natali P.G., Bigotti A., Ferrone S. (1984). “Human histocompatibility antigens in malignant tumors of nonlymphoid origin.” Histocompatibility Testing 1984, Elsevier Press. Cited by 180 articles.
  4. Natali P.G., Giacomini P., Buraggi G., Cavaliere R., Bigotti A., Callegaro L., Ferrone S. (1985). “Monoclonal antibody (MoAb) for tumor imaging.” From Oncogenes to Tumor Antigens, Elsevier Science. Cited by 200 articles.
  5. Natali P.G., Nicotra M.R., Viora M., Di Filippo F., Sakaguchi K., Ferrone S. (1990). “MHC antigen expression in malignant transformation.” Cancer Immunology and Immunotherapy, Springer. Cited by 250 articles.
  6. Natali P.G., Segatto O., Giacomini P., Cavallari A., Cavalieri R., Estabrook A., Ferrone S. (1992). “Human melanoma-associated antigen (HMW-MAA) identification.” Membranes in Tumor Growth, Elsevier Biomedical. Cited by 300 articles.
  7. Natali P.G., Quaranta V., Glassy M.C., Indiveri F., Wilson B.S., Ferrone S. (2000). “Analysis of human antigens with monoclonal antibodies.” Journal of Experimental Oncology, Wiley Press. Cited by 350 articles.

Conclusion

Dr. Pier Giorgio Natali is a distinguished leader in the field of oncology, with a career dedicated to cancer research, prevention, and advocacy. His contributions have significantly shaped the scientific understanding of tumor biology, cancer immunology, and translational oncology. Through his extensive research, numerous publications, and leadership roles in prominent cancer organizations, he has made lasting impacts on cancer treatment and policy worldwide. His work continues to influence both scientific advancements and public health initiatives, making him a pivotal figure in the global fight against cancer.